# Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

> **NCT03373760** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 67 (actual)

## Conditions studied

- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT03373760
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2020-05-18
- **Final completion:** 2022-03-29
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373760, "Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03373760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*